Stockscreener 앱 받기
120.30
5.53%
-7.04
시간 외 거래:
120.50
0.20
+0.17%
전일 마감가:
$127.34
열려 있는:
$127.27
하루 거래량:
179.49K
Relative Volume:
0.81
시가총액:
$1.73B
수익:
$1.30M
순이익/손실:
$-49.30M
주가수익비율:
-28.86
EPS:
-4.1688
순현금흐름:
$-29.10M
1주 성능:
-13.31%
1개월 성능:
-20.56%
6개월 성능:
-3.12%
1년 성능:
+64.48%
1일 변동 폭
$118.22
$127.27
1주일 범위
$118.22
$138.48
52주 변동 폭
$68.96
$161.38
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
120.30 | 1.73B | 1.30M | -49.30M | -29.10M | -4.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-21 | 재개 | Chardan Capital Markets | Buy |
| 2026-05-12 | 개시 | Stephens | Overweight |
| 2026-01-07 | 개시 | Mizuho | Outperform |
| 2025-12-05 | 개시 | BTIG Research | Buy |
| 2025-12-04 | 개시 | Craig Hallum | Buy |
| 2025-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-06 | 개시 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Therapeutics (PVLA) COO sells 4,302 shares under 10b5-1 plan - Stock Titan
Palvella (NASDAQ: PVLA) officer plans new stock sale after three recent trades - Stock Titan
Palvella Therapeutics director George M Jenkins sells $4.17 million in shares By Investing.com - Investing.com South Africa
Palvella Therapeutics director George M Jenkins sells $4.17 million in shares - Investing.com Canada
Director at Palvella Therapeutics (PVLA) sells 27,500 shares under trading plan - Stock Titan
Palvella Therapeutics director George M Jenkins sells $4.17 million in shares - Investing.com
Director at Palvella Therapeutics (NASDAQ: PVLA) plans multi-million-dollar stock sale - Stock Titan
Mizuho Securities Keeps Their Buy Rating on Palvella Therapeutics (PVLA) - theglobeandmail.com
Palvella Therapeutics Names James Treat Chief Medical Officer Ahead of QTORIN Commercialization - citybiz
Palvella at Cantor global healthcare conference: rare-disease push By Investing.com - Investing.com India
Palvella at Cantor global healthcare conference: rare-disease push By Investing.com - Investing.com Canada
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer - Yahoo Finance
KIRITSY CHRISTOPHER P Executes Palvella Therapeutics Options and Sells Shares at $157 on September 2, 2026 - Kalkine Media
Palvella CEO to Pitch Rare-Disease Pipeline at Investor Meets - MyChesCo
Palvella Therapeutics, Inc (NASDAQ: PVLA) Share Price, PVLA Stock News, PVLA Share Price & Updates - Kalkine
ICYMI: Palvella Seeks FDA Approval for Rare-Disease Skin Therapy - MyChesCo
Palvella Therapeutics (NASDAQ: PVLA) director exercises options, then sells 313 shares - Stock Titan
Palvella Therapeutics (NASDAQ: PVLA) investor to sell 375 shares - Stock Titan
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences - The Manila Times
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences - GlobeNewswire
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences - markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX) - theglobeandmail.com
Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240 - Moomoo
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - Barchart.com
86% of trial completers aged 6+ were much or very much improved - Stock Titan
36,259 Shares in Palvella Therapeutics, Inc. $PVLA Purchased by Blue Owl Capital Holdings LP - MarketBeat
Palvella Therapeutics COO Kathleen Goin Executes Stock Option Exercises and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells $654,807.42 in Stock - MarketBeat
Palvella Therapeutics (NASDAQ: PVLA) COO sells 4,302 shares under 10b5-1 plan - Stock Titan
Palvella Therapeutics, Inc (NASDAQ: PVLA) Share Price, PVLA Stock News, PVLA Share Price & Updates - kalkine.ca
Palvella (PVLA) Latest Quarter: EPS Comes in Below Forecast in the Available Record; Share Response: Shares Fall 6.03% for the Current SessionConsensus Forecast Report - vinanet.vn
Lisanti Capital Growth LLC Purchases Shares of 42,975 Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics (NASDAQ: PVLA) officer plans $647K share sale - Stock Titan
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel - Seeking Alpha
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands - MarketBeat
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands - TradingView
PRUDENTIAL FINANCIAL INC Establishes New Position in Palvella Th - GuruFocus
Palvella Therapeutics (PVLA): BVF group discloses 4.7% ownership stake in 13G/A - Stock Titan
First Light Asset Management (PVLA) discloses 5.34% Palvella Therapeutics stake in client accounts - Stock Titan
Palvella at Canaccord Genuity’s 46th Annual Growth Conference: launch prep By Investing.com - Investing.com Canada
Palvella (PVLA) Q2 2026 Earnings Call Transcript - AOL.com
Palvella (PVLA) Q2 2026 Earnings Call Transcript - theglobeandmail.com
Prudential Financial (PVLA) reports 6.7% beneficial ownership in Palvella Therapeutics - Stock Titan
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance Australia
Palvella Therapeutics, Inc. (PVLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Palvella Therapeutics, Inc. $PVLA Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval? - Yahoo Finance
Jennison Associates Expands Palvella Therapeutics (PVLA) Stake i - GuruFocus
Palvella Therapeutics Inc (PVLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palvella Therapeutics Inc (PVLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Palvella Therapeutics Inc 주식 (PVLA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| JENKINS GEORGE M | Director |
Oct 14 '26 |
Sale |
123.49 |
7,174 |
885,914 |
132,616 |
| JENKINS GEORGE M | Director |
Oct 13 '26 |
Proposed Sale |
134.38 |
27,500 |
3,695,450 |
0 |
| JENKINS GEORGE M | Director |
Oct 13 '26 |
Sale |
130.36 |
7,174 |
935,232 |
139,790 |
| Goin Kathleen | Officer |
Sep 16 '26 |
Proposed Sale |
151.22 |
4,302 |
650,548 |
0 |
| Goin Kathleen | Chief Operating Officer |
Sep 16 '26 |
Option Exercise |
8.11 |
4,302 |
34,883 |
4,302 |
| Goin Kathleen | Chief Operating Officer |
Sep 16 '26 |
Sale |
152.24 |
4,302 |
654,923 |
0 |
| JENKINS GEORGE M | Director |
Sep 15 '26 |
Sale |
150.14 |
1,777 |
266,806 |
160,116 |
| JENKINS GEORGE M | Director |
Sep 14 '26 |
Sale |
151.96 |
13,352 |
2,028,905 |
161,893 |
| JENKINS GEORGE M | Director |
Sep 11 '26 |
Sale |
151.28 |
12,371 |
1,871,435 |
175,245 |
| JENKINS GEORGE M | Director |
Sep 11 '26 |
Proposed Sale |
150.39 |
27,500 |
4,135,725 |
0 |
4.80%
자본화:
|
볼륨(24시간):